High-sensitivity C-reactive protein and cardiovascular disease

A resolute belief or an elusive link?

Omair Yousuf, Bibhu D. Mohanty, Seth S. Martin, Parag H. Joshi, Michael J. Blaha, Khurram Nasir, Roger S. Blumenthal, Matthew J. Budoff

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

The role of inflammation in the propagation of atherosclerosis and susceptibility to cardiovascular (CV) events is well established. Of the wide array of inflammatory biomarkers that have been studied, high-sensitivity C-reactive protein (hsCRP) has received the most attention for its use in screening and risk reclassification and as a predictor of clinical response to statin therapy. Although CRP is involved in the immunologic process that triggers vascular remodeling and plaque deposition and is associated with increased CV disease (CVD) risk, definitive randomized evidence for its role as a causative factor in atherothrombosis is lacking. Whether measurement of hsCRP levels provides consistent, clinically meaningful incremental predictive value in risk prediction and reclassification beyond conventional factors remains debated. Despite publication of guidelines on the use of hsCRP in CVD risk prediction by several leading professional organizations, there is a lack of clear consensus regarding the optimal clinical use of hsCRP. This article reviews 4 distinct points from the literature to better understand the current state and application of hsCRP in clinical practice: 1) the biology of hsCRP and its role in atherosclerosis; 2) the epidemiological association of hsCRP with CVD; 3) the quality of hsCRP as a biomarker of risk; and 4) the use of hsCRP as a tool to initiate or tailor statin therapy. Furthermore, we highlight recommendations from societies and important considerations when using hsCRP to guide treatment decisions in the primary prevention setting.

Original languageEnglish (US)
Pages (from-to)397-408
Number of pages12
JournalJournal of the American College of Cardiology
Volume62
Issue number5
DOIs
StatePublished - Jul 30 2013

Fingerprint

C-Reactive Protein
Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atherosclerosis
Biomarkers
Primary Prevention
Publications
Guidelines
Inflammation
Therapeutics

Keywords

  • atherosclerosis
  • cardiovascular disease
  • coronary heart disease
  • CRP
  • hsCRP
  • inflammation
  • prevention
  • statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

High-sensitivity C-reactive protein and cardiovascular disease : A resolute belief or an elusive link? / Yousuf, Omair; Mohanty, Bibhu D.; Martin, Seth S.; Joshi, Parag H.; Blaha, Michael J.; Nasir, Khurram; Blumenthal, Roger S.; Budoff, Matthew J.

In: Journal of the American College of Cardiology, Vol. 62, No. 5, 30.07.2013, p. 397-408.

Research output: Contribution to journalArticle

Yousuf, Omair ; Mohanty, Bibhu D. ; Martin, Seth S. ; Joshi, Parag H. ; Blaha, Michael J. ; Nasir, Khurram ; Blumenthal, Roger S. ; Budoff, Matthew J. / High-sensitivity C-reactive protein and cardiovascular disease : A resolute belief or an elusive link?. In: Journal of the American College of Cardiology. 2013 ; Vol. 62, No. 5. pp. 397-408.
@article{e29323a297f74dc4b76e7d663e6573da,
title = "High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link?",
abstract = "The role of inflammation in the propagation of atherosclerosis and susceptibility to cardiovascular (CV) events is well established. Of the wide array of inflammatory biomarkers that have been studied, high-sensitivity C-reactive protein (hsCRP) has received the most attention for its use in screening and risk reclassification and as a predictor of clinical response to statin therapy. Although CRP is involved in the immunologic process that triggers vascular remodeling and plaque deposition and is associated with increased CV disease (CVD) risk, definitive randomized evidence for its role as a causative factor in atherothrombosis is lacking. Whether measurement of hsCRP levels provides consistent, clinically meaningful incremental predictive value in risk prediction and reclassification beyond conventional factors remains debated. Despite publication of guidelines on the use of hsCRP in CVD risk prediction by several leading professional organizations, there is a lack of clear consensus regarding the optimal clinical use of hsCRP. This article reviews 4 distinct points from the literature to better understand the current state and application of hsCRP in clinical practice: 1) the biology of hsCRP and its role in atherosclerosis; 2) the epidemiological association of hsCRP with CVD; 3) the quality of hsCRP as a biomarker of risk; and 4) the use of hsCRP as a tool to initiate or tailor statin therapy. Furthermore, we highlight recommendations from societies and important considerations when using hsCRP to guide treatment decisions in the primary prevention setting.",
keywords = "atherosclerosis, cardiovascular disease, coronary heart disease, CRP, hsCRP, inflammation, prevention, statins",
author = "Omair Yousuf and Mohanty, {Bibhu D.} and Martin, {Seth S.} and Joshi, {Parag H.} and Blaha, {Michael J.} and Khurram Nasir and Blumenthal, {Roger S.} and Budoff, {Matthew J.}",
year = "2013",
month = "7",
day = "30",
doi = "10.1016/j.jacc.2013.05.016",
language = "English (US)",
volume = "62",
pages = "397--408",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - High-sensitivity C-reactive protein and cardiovascular disease

T2 - A resolute belief or an elusive link?

AU - Yousuf, Omair

AU - Mohanty, Bibhu D.

AU - Martin, Seth S.

AU - Joshi, Parag H.

AU - Blaha, Michael J.

AU - Nasir, Khurram

AU - Blumenthal, Roger S.

AU - Budoff, Matthew J.

PY - 2013/7/30

Y1 - 2013/7/30

N2 - The role of inflammation in the propagation of atherosclerosis and susceptibility to cardiovascular (CV) events is well established. Of the wide array of inflammatory biomarkers that have been studied, high-sensitivity C-reactive protein (hsCRP) has received the most attention for its use in screening and risk reclassification and as a predictor of clinical response to statin therapy. Although CRP is involved in the immunologic process that triggers vascular remodeling and plaque deposition and is associated with increased CV disease (CVD) risk, definitive randomized evidence for its role as a causative factor in atherothrombosis is lacking. Whether measurement of hsCRP levels provides consistent, clinically meaningful incremental predictive value in risk prediction and reclassification beyond conventional factors remains debated. Despite publication of guidelines on the use of hsCRP in CVD risk prediction by several leading professional organizations, there is a lack of clear consensus regarding the optimal clinical use of hsCRP. This article reviews 4 distinct points from the literature to better understand the current state and application of hsCRP in clinical practice: 1) the biology of hsCRP and its role in atherosclerosis; 2) the epidemiological association of hsCRP with CVD; 3) the quality of hsCRP as a biomarker of risk; and 4) the use of hsCRP as a tool to initiate or tailor statin therapy. Furthermore, we highlight recommendations from societies and important considerations when using hsCRP to guide treatment decisions in the primary prevention setting.

AB - The role of inflammation in the propagation of atherosclerosis and susceptibility to cardiovascular (CV) events is well established. Of the wide array of inflammatory biomarkers that have been studied, high-sensitivity C-reactive protein (hsCRP) has received the most attention for its use in screening and risk reclassification and as a predictor of clinical response to statin therapy. Although CRP is involved in the immunologic process that triggers vascular remodeling and plaque deposition and is associated with increased CV disease (CVD) risk, definitive randomized evidence for its role as a causative factor in atherothrombosis is lacking. Whether measurement of hsCRP levels provides consistent, clinically meaningful incremental predictive value in risk prediction and reclassification beyond conventional factors remains debated. Despite publication of guidelines on the use of hsCRP in CVD risk prediction by several leading professional organizations, there is a lack of clear consensus regarding the optimal clinical use of hsCRP. This article reviews 4 distinct points from the literature to better understand the current state and application of hsCRP in clinical practice: 1) the biology of hsCRP and its role in atherosclerosis; 2) the epidemiological association of hsCRP with CVD; 3) the quality of hsCRP as a biomarker of risk; and 4) the use of hsCRP as a tool to initiate or tailor statin therapy. Furthermore, we highlight recommendations from societies and important considerations when using hsCRP to guide treatment decisions in the primary prevention setting.

KW - atherosclerosis

KW - cardiovascular disease

KW - coronary heart disease

KW - CRP

KW - hsCRP

KW - inflammation

KW - prevention

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84880606957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880606957&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.05.016

DO - 10.1016/j.jacc.2013.05.016

M3 - Article

VL - 62

SP - 397

EP - 408

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -